The initial facilities in the South Warwickshire region adopting the technology include the Stratford Upon Avon and Warwick hospitals, with a wider rollout planned as vaccine distribution progresses.
The various COVID-19 vaccines, including the one developed by Pfizer and now approved for use in the UK, require exact degrees of cold storage at all times in order to maintain their efficacy.
While centralized distribution centers and transportation units can store the vaccine at the recommended -70°C±10°C for up to 10 days unopened, they must also be stored at hospitals and other administering centers for five days at refrigerated 2-8°C conditions.
Everyware provides asset tracking and monitoring software that can be configured to monitor a number of variables, including temperature, on a 24/7 basis, from anywhere.
By leveraging Everyware's asset monitoring solution at the 'last mile', hospitals and healthcare facilities can ensure that vaccines are being maintained at the proper temperature throughout the entire time in their custody, before they are administered to patients.
In addition, Everyware enables healthcare facilities to share information with other parts of the vaccine delivery chain including pharmaceutical providers, centralized storage facilities, and transportation companies, to respond and adjust to any issues as they arise.
Everyware's offering already provides this service for a number of other healthcare and pharmaceutical assets, including chemotherapy and other drugs, and blood and plasma, all of which have their own unique storage requirements.
Hedera is a decentralized public platform on which developers can build secure, fair, fast, trusted applications.
The platform is governed by a council of the world's leading organizations including Avery Dennison, Boeing, Deutsche Telekom, Dentons, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London, Wipro, and Zain Group.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses